FibroGen Announces Positive Topline Results from China Pivotal Phase 3 Clinical Trial of Roxadustat for the Treatment of Chemotherapy Induced Anemia

Source :: GlobeNewswire. May 18, 2023
Publication Year :: 2023
Abstract: Met primary endpoint of noninferiority of roxadustat to erythropoietin alfa Plan to file supplemental New Drug Application in China SAN FRANCISCO and BEIJING, May 18, 2023 (GLOBE NEWSWIRE) -- FibroGen, [...]

Subjects :: FibroGen Inc. -- Product development -- Company sales and earnings -- Planning
AstraZeneca PLC -- Company sales and earnings -- Product development -- Planning
Anemia -- Drug therapy
Biotechnology industry -- Company sales and earnings -- Product development -- Planning
Erythropoietin, Recombinant
Clinical trials
Pharmaceutical industry -- Product development -- Company sales and earnings -- Planning
Company business planning
Company earnings/profit
Banking, finance and accounting industries
Business

Tools